Novavax, an American vaccine development company, completed the acquisition of Praha Vaccines, a Czech vaccination company, for c.$167m. “Manufacturing capacity is a critical component of our strategy to deliver a vaccine for the Covid-19 pandemic. This acquisition provides the vital assets required to produce more than 1bn doses per year. In parallel with ramping up production at Bohumil, we will continue efforts to expand antigen capacity in the US and Asia, and increase the production of Matrix-M to match antigen capacity at multiple sites globally,” Stanley C. Erck, Novavax President and Chief Executive Officer.